EP1899333B1 - Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 - Google Patents

Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 Download PDF

Info

Publication number
EP1899333B1
EP1899333B1 EP06754324A EP06754324A EP1899333B1 EP 1899333 B1 EP1899333 B1 EP 1899333B1 EP 06754324 A EP06754324 A EP 06754324A EP 06754324 A EP06754324 A EP 06754324A EP 1899333 B1 EP1899333 B1 EP 1899333B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkylene
group
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06754324A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1899333A1 (en
Inventor
Henning Steinhagen
Jochen Huber
Kurt Ritter
Bernard Pirard
Kirsten Bjergarde
Marcel Patek
Martin Smrcina
Linli Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to PL06754324T priority Critical patent/PL1899333T3/pl
Priority to SI200630284T priority patent/SI1899333T1/sl
Priority to EP06754324A priority patent/EP1899333B1/en
Publication of EP1899333A1 publication Critical patent/EP1899333A1/en
Application granted granted Critical
Publication of EP1899333B1 publication Critical patent/EP1899333B1/en
Priority to CY20091100501T priority patent/CY1110464T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the sympathetic nervous system that is a critical regulator of cardiac function has been implicated in the inability of the failing heart to respond to stress or injury.
  • catecholamines i.e. the sympathetic neurotransmitter norepinephrine and the adrenal hormon epinephrine
  • ARs myocardial adrenergic receptors
  • These receptors which include ⁇ 1 and ⁇ 2 ARs modulate cardiac function by coupling to and activating G proteins and thus belong to the large superfamily of G protein coupled receptors (GPCRs).
  • GPCRs G protein coupled receptors
  • the interaction results in the dissociation of the G-protein heterotrimer into two components, namely the Ga- and G ⁇ subunits. Either of these two subunits can modulate cytosolic effector proteins that in turn may regulate production of intracellular messenger molecules.
  • cytosolic effector proteins that in turn may regulate production of intracellular messenger molecules.
  • Gs a specific G-protein, Gs, stimulates adenylyl cyclase to produce cAMP within the cell, which increases cardiac chronotropy and inotropy ( Petrofski and Koch, J. Mol. Cell. Cardiol. 2003, 35, 1167-1174 ).
  • G-protein coupled receptor kinases Seven GRK family members have been identified to date. Two (GRK1 or rhodopsin kinase and GRK7) are localized primarily in the retina, whereas the remaining five (GRK2-7) are ubiquitously expressed in several tissues including the heart. GRKs have a tridomain structure with a central catalytic domain, flanked by amino-terminal (NT) and carboxy-terminal (CT) domains that contain specific regulatory sites ( laccarino and Koch, Assay and Drug Develop. Technol. 2003, 1(2), 347-355 ).
  • NT amino-terminal
  • CT carboxy-terminal
  • G ⁇ binding takes place with an approximate 100 amino acid stretch that is part part of the pleckstrin homology (PH) domain found in the CT of GRK2.
  • PH pleckstrin homology
  • Desensitization may be an adaptive response to GPCR stimulation, but can also lead to pathological loss of receptor signaling.
  • chronic activation of the sympathetic nervous system has adverse implications and can accelerate cardiac pathology.
  • Constant stimulation of adrenergic receptors by catecholamines leads to selective ⁇ 1AR downregulation ( Bristow et al., New Engl. J. Med. 1982, 307 (4), 205-211 ).
  • GRK2 mRNA and protein, and activity-are elevated approximately threefold and this causes dysfunctional ⁇ AR signaling and the loss of inotropic reserve in the frailing heart Ungerer et al., Circulation 1993, 87, 454-463 .
  • myocardial ischemia and hypertension both important causes in heart failure, are also correlated with elevated GRK2 levels ( Petrofski and Koch, J. Mol. Cell. Cardiol. 2003, 35, 1167-1174 ).
  • GRK2 inhibitors may be of value in the treatment of hypertension since elevated GRK2 levels have been demonstrated in peripheral blood lymphocytes of a subgroup of hypertensive patients with impaired ⁇ 2AR-mediated vasodilation. Because ⁇ 1AR regulation in lymphocytes parallels that observed in vascular smooth muscle cells in hypertensive subjects, the GRK2 up-regulation seen in these lymphocytes is suggested to underlie the attenuation of ⁇ 2AR-mediated vasodilation in the hypertensive subjects studied ( Gros R et al., J. Clin. Invest. 1997, 99, 2087-2093 ).
  • GRK2 inhibitors may be also be applied in the treatment of myocardial ischemia since elevated GRK2 levels could be demonstrated in rat heart muscle deprived of oxygen for prolonged periods and this up-regulation correlates temporally with diminishing responsiveness of ⁇ -adrenergic receptor stimulated cyclase activity ( Ungerer et al., Circ. Res. 1996, 79, 455-460 ).
  • GRK2 inhibitors can be used to prevent opiate addiction.
  • the increased GRK2 activity may both compensate for hyperstimulation of central nervous system opioid receptors and contribute to the problem of opiate tolerance ( Terwilliger et al., J. Neurochem 1994, 63, 1983-1986 ).
  • GRK2 (among other protein kinases, metalloproteases and phosphatases) is a potential target for medical intervention against hepatitis C virus (HCV) infections.
  • G-protein coupled receptor kinases 2 GRK2
  • ⁇ ARK-1 ⁇ -Adrenergic Receptor Kinase 1
  • WO 2004/076450 describes 6-heterocyclyl or phenyl substituted pyrazolopyridine derivatives useful as p38 kinase inhibitors.
  • WO 03/068773 describes pyrazolopyridine derivatives as GSK-3 inhibitors useful for a variety of indications wherein the 6-position is optionally substituted by (C 3 -C 8 )cycloalkyl, heterocyclyl, heteroaryl or aryl.
  • WO 03/045949 describes pyrazolopyridine derivatives as GSK-3 inhibitors wherein the 6-position is unsubstituted.
  • WO 95/34563 and EP 1149583 describes generically describes pyrazolopyridine derivatives useful as CRF antagonists wherein the 6-position is substituted by (C 1 -C 4 ) alkyl, fluoro, chloro, bromo, iodo, -CH 2 OH, -CH 2 OCH 3 , -O(C 1 -C 3 )alkyl, -S(C 1 -C 3 )alkyl, or -SO 2 (C 1 -C 3 )alkyl.
  • the present invention relates to compounds of the formula (I) wherein
  • (C 1 -C 4 )alkyl, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylene are understood as a hydrocarbon residue which can be linear, i.e. straight-chain, or branched and has 1, 2, 3 or 4, or 1, 2, 3, 4, 5 or 6 carbon atoms, respectively. This also applies if an alkyl group occurs as a substituent on another group, for example in an alkoxy group (O-alkyl), a thio group (S-alkyl) or a -O(CH 2 ) n -O-, an alkoxycarbonyl group or an arylalkyl group.
  • alkyl groups are methyl, ethyl, propyl, butyl, pentyl or hexyl, the n-isomers of all these groups, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tert-butyl or tert-pentyl.
  • Alkyl groups may - if not otherwise stated - be halogenated once or more, i.e. alkyl groups may be fluorinated, i.e. perfluorinated. Examples of halogenated alkyl groups are CF 3 and CH 2 CF 3 , OCF 3 , S-CF 3 , -O-(CF 2 ) 2 -O-.
  • (C 3 -C 10 )cycloalkyl groups are cyclic alkyl groups containing 3, 4, 5, 6, 7, 8, 9 or 10 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl, which can also be substituted and/or unsaturated.
  • Unsaturated cyclic alkyl groups and unsaturated cycloalkyl groups like, for example, tetrahydronaphthyl, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.
  • alkyl as used herein also comprises cycloalkyl- substituted alkyl groups like cyclopropylmethyl-, cyclobutylmethyl-, cyclopentylmethyl-, 1-cyclopropylethyl-, 1-cyclobutylethyl-, 1-cyclopentylethyl-, 2-cyclopropylethyl-, 2-cyclobutylethyl-, 2-cyclopentylethyl-, 3-cyclopropylpropyl-, 3-cyclobutylpropyl-, etc. in which groups the cycloalkyl subgroup as well as acyclic subgroup can be unsaturated and/or substituted.
  • a cyclic alkyl group has to contain at least three carbon atoms, and an unsaturated alkyl group has to contain at least two carbon atoms.
  • a group like (C 1 -C 4 )-alkyl is to be understood as comprising, among others, saturated acyclic (C 1 -C 4 )-alkyl, (C 3 -C 4 )-cycloalkyl, cyclopropyl-methyl.
  • a (C 6 -C 10 )aryl group means an aromatic ring or a ring system which comprises two aromatic rings which are fused or otherwise linked, for example a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha- or beta-tetralon-, indanyl- or indan-1-on-yl group. Phenyl is a preferred (C 6 -C 10 )aryl group.
  • a (C 4 -C 10 )heterocyclyl group means a 4-10 membered mono- or bicyclic ring system which comprises, apart from carbon, one or more heteroatoms such as, for example, 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or combinations of different hetero atoms.
  • a C 6 -heterocyclyl may contain 5 carbon atoms and 1 nitrogen atom as is the case in pyridyl or piperidinyl.
  • the heterocyclyl residues can be bound at any positions, for example on the 1-position, 2-position, 3-position, 4-position, 5-position, 6-position, 7-position or 8-position.
  • Heterocyclyl comprises (1) aromatic (C 5 -C 10 )heterocyclyl groups [(C 5 -C 10 )heteroaryl groups] or (2) saturated (C 4 -C 10 )heterocyclyl groups or (3) mixed aromatic/saturated fused (C 8 -C 10 )heterocyclyl groups.
  • (C 5 -C 10 )heteroaryl groups are preferred as (C 4 -C 10 )heterocyclyl group.
  • Suitable (C 4 -C 10 )heterocyclyl group include acridinyl, azetidine, benzimidazolyl, benzofuryl, benzomorpholinyl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, furanyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuran, furyl, furazanyl, homo
  • Preferred examples of (C 4 -C 10 )heterocyclyl residues are 2- or 3-thienyl, 2 or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1-, -4 or -5-yl, 1,2,4-triazol-1-, -3 or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazol-4 or -5-yl, 1,2,4-oxadiazol-3 or -5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 1,3,4-thiadiazol-2 or -5-yl, 1,2,4-thiadiazol-3 or -5-yl, 1,2,3-thiadiazol-4
  • n-oxides for example 1-oxy-2 -, -3 or -4-pyridyl.
  • Particularly preferred (C 4 -C 10 )heterocyclyl residues are 2- or 3-furyl, 2- or 3-pyrrolyl, 3 -, 4- or 5-pyrazolyl, and 2-, 3- or 4-pyridyi.
  • the substituent can be located in the 2-position, the 3-position or the 4-position, with the 3-position and the 4-position being preferred. If a phenyl group carries two substituents, they can be located in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In phenyl groups carrying three substituents the substituents can be located in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position, or 3,4,5-position.
  • phenyl groups correspondingly apply to divalent groups derived from phenyl groups, i.e. phenylene which can be unsubstituted or substituted 1,2-phenylene, 1,3-phenylene or 1,4-phenylene.
  • the above statements also correspondingly apply to the aryl subgroup in arylalkylene groups.
  • arylalkylene groups which can also be unsubstituted or substituted in the aryl subgroup as well as in the alkylene subgroup, are benzyl, 1-phenylethylene, 2-phenylethylene, 3-phenylpropylene, 4-phenylbutylene, 1-methyl-3-phenyl-propylene.
  • Halogen means fluoro, chloro, bromo or iodo.
  • a preferred embodiment of the present invention is a compound of the formula (I) wherein R 1 and R 3 are as defined above; and R 2 is phenyl or a (C 4 -C 10 )heterocyclyl group which are unsubstituted or substituted as defined above.
  • a further preferred embodiment of the present invention is a compound of the formula (I) wherein
  • a further preferred embodiment of the present invention is a compound of the formula (I) wherein.
  • a further preferred embodiment of the present invention is a compound of the formula (I) wherein
  • a further preferred embodiment of the present invention is a compound of the formula (I) wherein
  • Preferred (C 5 -C 10 )heteroaryl groups as group R 2 are benzofuranyl, indolyl, furanyl, pyridyl, pyrrolyl, pyrazolyl, pyrazinyl, pyrimidyl, quinolinyl, thienyl, tetrazolyl, triazolyl.
  • R 2 group is (C 5 -C 10 )heteroaryl of the formula (II), wherein
  • a further preferred embodiment of the present invention is a compound of the formula (I) wherein
  • Optically active carbon atoms present in the compounds of the formula (I) can independently of each other have R configuration or S configuration.
  • the compounds of the formula (I) can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers and/or diastereomers, for example in the form of racemates.
  • the present invention relates to pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers.
  • the invention comprises mixtures of two or of more than two stereoisomers of the formula I, and it comprises all ratios of the stereoisomers in the mixtures.
  • the invention relates both to pure E isomers and pure Z isomers and to E/Z mixtures in all ratios.
  • the invention also comprises all tautomeric forms of the compounds of the formula (I).
  • Diastereomers including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by customary methods, for example by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases. Stereochemically unifom compounds of the formula (I) can also be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.
  • Physiologically acceptable salts of the compounds of formula (I) are nontoxic salts that are physiologically acceptable, in particular pharmaceutically utilizable salts.
  • Such salts of compounds of the formula (I) containing acidic groups, for example a carboxylic group COOH are for example alkali metal salts or alkaline earth metal salts such as sodium salts, potassium salts, magnesium salts and calcium salts, and also salts with physiologically acceptable quaternary ammonium ions such as tetramethylammonium or tetraethylammonium, and acid addition salts with ammonia and physiologically acceptable organic amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, ethanolamine or tris-(2-hydroxyethyl)-amine.
  • Basic groups contained in the compounds of the formula I form acid addition salts, for example with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid.
  • the present invention also includes acid addition salts of compounds of the formula (I) which contain, for example, two basic groups, with one or two acid equivalents.
  • Salts of compounds of the formula (I) can be obtained by customary methods known to those skilled in the art, for example by combining a compound of the formula (I) with an inorganic or organic acid or base in a solvent or diluent, or from other salts by cation exchange or anion exchange.
  • the present invention also includes all salts of the compounds of the formula (I) which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of the formula (I) or as starting materials for the preparation of physiologically acceptable salts.
  • anions of the mentioned acids that may be present in acid addition salts of the compounds of the formula I, are also examples of anions that may be present in the compounds of the formula (I) if they contain one or more positively charged groups like trialkylammonio- substituents, i. e. groups of the formula (alkyl) 3 N bonded via the positively charged nitrogen atom, representing R, or quaternized ring nitrogen atoms in heterocyclic groups.
  • a compound of the formula (I) contains one or more physiologically acceptable anions or anion equivalents as counterions if it contains one or more permanently positively charged groups like trialkylammonio.
  • the present invention furthermore includes all solvates of compounds of the formula (I), for example hydrates or adducts with alcohols.
  • the compounds of the formula (I), which on account of its chemical structure occurs in enantiomeric forms, can be resolved into the pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds such as amino acids, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups.
  • the compounds of the formula (I) can be isolated either in free form or, in the case of the presence of acidic or basic groups, converting it into physiologically acceptable salts.
  • the preparation of physiologically acceptable salts of compounds of the formula (I) capable of salt formation, including their stereoisomeric forms, is carried out in a manner known per se.
  • basic reagents such as hydroxides, carbonates, hydrogencarbonates, alkoxides and also ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or alternatively basic amino acids, for example lysine, ornithine or arginine
  • the carboxylic acids form stable alkali metal, alkaline earth metal or optionally substituted ammonium salts.
  • stable acid addition salts can also be prepared using strong acids.
  • inorganic and organic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, benzenesulfonic, p-toluenesulfonic, 4-bromobenzenesulfonic, cyclohexylamidosulfonic, trifluoromethylsulfonic, acetic, oxalic, tartaric, succinic or trifluoroacetic acid are suitable.
  • the present invention therefore also relates to the compounds of the formula (I) and/or their physiologically acceptable salts for use as pharmaceuticals (or medicaments), to the use of the compounds of the formula (I) and/or their physiologically acceptable salts for the production of pharmaceuticals for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
  • pharmaceuticals for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
  • HCV hepatitis C virus
  • the present invention furthermore relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an effective amount of at least one compound of the formula (I) and/or its physiologically acceptable salts and a pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • a pharmaceutically acceptable carrier i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • the pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures.
  • Administration can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.
  • compositions according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) physiologically acceptable salts.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) physiologically acceptable salts.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) physiologically acceptable salts.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formula (I) and/or its (their) physiologically acceptable salts.
  • Carrier substances for soft gelatin capsules and suppositories are, for example, fat
  • Suitable carrier substances for the production of solutions for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc.
  • Suitable carrier substances for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
  • the pharmaceutical preparations normally contain about 0.5 to about 90 % by weight of the compounds of the formula (I) and/or their physiologically acceptable salts.
  • the amount of the active ingredient of the formula (I) and/or its physiologically acceptable salts and/or its prodrugs in the pharmaceutical preparations normally is from about 0.5 to about 1000 mg, preferably from about 1 to about 500 mg.
  • the pharmaceutical preparations can contain one or more additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula (I) and/or their physiologically acceptable salts.
  • a pharmaceutical preparation contains two or more compounds of the formula (I) the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower potency.
  • the flexibility permitted with respect to the choice of substituents in the compounds of the formula (I) allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds.
  • the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients.
  • the compounds of the formula (I) and their physiologically acceptable salts are generally suitable for the therapy and prophylaxis of conditions in which the activity of GRK2 or ⁇ ARK-1 plays a role or has an undesired extent, or which can favorably be influenced by inhibiting GRK2 or ⁇ ARK-1 or decreasing its activity, or for the prevention, alleviation or cure of which an inhibition of GRK2 or ⁇ ARK-1 or a decrease in its activity is desired by the physician.
  • the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out.
  • An appropriate dosage can be established using clinical approaches well known in the medical art.
  • the daily dose for achieving the desired results in an adult weighing about 75 kg is from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 10 mg/kg, (in each case in mg per kg of body weight).
  • the daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.
  • the compounds of the formula (I) can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.
  • the compounds of the formula (I) can generally be prepared according to the following scheme:
  • R 2 -aldehyde (II), 3-aminopyrazole (III) and R 3 -containing methyl pyruvate (IV) are mixed in dichloroethane (DCE) in the presence of an acid, preferably acetic acid, and the mixture is heated to 50-120°C, preferably 60-100°C, and subsequently the reaction mixture is oxidized, preferably by exposure to air whereby the aromatic 1H-Pyrazolo[3,4-b]pyridine system (VI) is formed.
  • DCE dichloroethane
  • R 2 -aldehyde (II), 3-aminopyrazole (III) and R 3 -containing pyruvic acid (V) are mixed in ethanol and heated to 50-120°C, preferably 60-100°C. Subsequent oxidization, preferably by exposure to air yields the 1 H-Pyrazolo[3,4-b]pyridine acid derivative (VII).
  • Ester cleavage can be achieved by standard methods by e.g. exposing the ester (VI) base. Details on methods for the preparation are given in various standard reference like, for example, J. March, Advanced Organic Chemistry, 4th ed., John Wiley & Sons, 1992 .
  • the respective amides of the formula (I) wherein R 1 is hydrogen can be formed by reacting the ester (VI) with a suitable reagent such as e.g. ammonia in methanol or by activating the carboxylic acid derivative (VII) with Boc 2 O and treating the resulting tert-butyl ester with NH 4 HCO 3 .
  • a suitable reagent such as e.g. ammonia in methanol
  • Boc 2 O e.g. ammonia in methanol
  • Boc 2 O e.g. Boc 2 O
  • NH 4 HCO 3 e.g.
  • a tert-butyl ester is formed at N1 or N2 of the pyrazolopyridine, it can be removed by treatment with TFA.
  • Compounds of the formula (I) wherein R 1 is an optionally substituted (C 1 -C 6 )alkyl group can be obtained by coupling the respective (C 1 -C 6 )alkyl-NH 2 derivative (VIII) to (VII) in the presence of a standard coupling reagent such as e.g. DIC, dicyclohecyl carbodiimide, EDC, HOBT etc.
  • a standard coupling reagent such as e.g. DIC, dicyclohecyl carbodiimide, EDC, HOBT etc.
  • tert-butyl protecting groups in particular a tert-butoxycarbonyl group which is a protected form of an amidino group
  • tert-butoxycarbonyl group which is a protected form of an amidino group
  • functional groups can be generated from suitable precursor groups.
  • a conversion into a physiologically acceptable salt or a prodrug of a compound of the formula (I) can then be carried out by known processes.
  • a reaction mixture containing a final compound of the formula (I) or an intermediate is worked up and, if desired, the product is then purified by customary processes known to those skilled in the art.
  • a synthesized compound can be purified using well known methods such as crystallization, chromatography or reverse phase-high performance liquid chromatography (RP-HPLC) or other methods of separation based, for example, on the size, charge or hydrophobicity of the compound.
  • RP-HPLC reverse phase-high performance liquid chromatography
  • well known methods such as amino acid sequence analysis, NMR, IR and mass spectrometry (MS) can be used for characterizing a compound of the invention.
  • step 1 The compound derived from step 1 (0.5g, 1.9mmol) was dissolved in DCM (10mL) and to the solution was added 48% HBr (3.0mL). This solution was allowed to stir overnight at r.t. The solvent was evaporated to give a dark purple solid. The crude was triturated twice with ethyl acetate, (following subsequent removal of ethyl acetate under reduced pressure). The crude material was purified by column chromatography. Conditions: 0.75g of crude compound on 25g of flash grade silica; hexanes/ethyl acetate (50/50).
  • Step 1 Synthesis of 4- ⁇ -4-[2-(2-pyridyloxy)ethyl]-1-methyl- 1H -indolyl ⁇ -6-methoxycarbonyl-7-aza-indazole:
  • the raw product from step 1 was dissolved into 2ml of 7 N NH 3 /MeOH, sealed and heated at 80 °C for 6 h and the solvent was removed under reduced pressure.
  • the residue was purified via prep-HPLC (RP YMC-Pack ODS-AM, AM12S05-2520WT, S-5um, 12nm, gradient ACN/water(+0.1 % TFA), 10-100 % in 20 min, 10ml/min, UV detection 280nm) and after lyophilization 1 mg pure product (1 % overall yield) were obtained.
  • step 1 The product obtained from step 1 (200 mg, 385 ⁇ mol) was treated with 20 ml 7N ammonia in methanol at 70 °C for 3 h, and evaporated to dryness. The solid was treated with 50% TFA in DCM (6 ml) for 2 h, and evaporated to dryness. Purification by prep-HPLC (in water with 0.1 % TFA using a gradient of 5 to 45 % ACN over 3 minutes) yielded 40 mg (yield: 48 %) of the product as a solid.
  • Step 1 Synthesis of 4-(1-Methyl- 1H -indol-3-yl)- 1H -indazole-6-carboxylic acid methyl ester
  • the solid was dissolved in pyridine/ethyl acetate 1:1 (60 ml) and treated with ammonium bicarbonate (948 mg, 12 mmol) and di-tert-butyl dicarbonate (2.19g, 12 mmol) for 16h at r.t. The mixture was then evaporated to dryness, redissolved in ethyl acetate (100 ml), and washed with water/brine (3x), dried (Na 2 SO 4 ), filtered, and evaporated to dryness.
  • Example 55 which was prepared in analogy to example 5 yielding the corresponding carboxylic acid and was subsequently coupled with aminoethanol according to standard amid coupling conditions using DIC as coupling reagent.
  • the LC/MS system used to obtain the r.t. and MS main peak data was a Waters 2790-ZQ, the column a YMC ProC18 S-5120A 2x50 mm, the method was 0.1% TFA in water with a gradient of ACN 2-85% over 6.85 minutes.
  • MS ionization method was ESI technique.
  • the assay determines phosphorylation of biotinylated bovine tubulin dimers (250 nM; TEBU-BIO, # T333) coated to 384 well StreptaWell plates by 100 nM GRK2 which has been pre-incubated with inhibitor cpd. for 30 minutes at room temperature in assay buffer (20 mM Tris-HCl pH 7.4, 2 mM EDTA) containing 2.25% DMSO.
  • the phosphorylation reaction was started by adding tubulin, MgCl 2 (10 mM), ATP (3 ⁇ M), [ ⁇ - 33 P]-ATP (0.4 ⁇ Ci/40 ⁇ l) to the preincubated GRK2/compound complex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP06754324A 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 Active EP1899333B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL06754324T PL1899333T3 (pl) 2005-06-27 2006-06-13 Pochodne pirazolopirydyny jako inhibitory kinazy 1 receptora beta-adrenergicznego
SI200630284T SI1899333T1 (sl) 2005-06-27 2006-06-13 Pirazolopiridinski derivati kot inhibitorji kinaze 1 betaadrenergičnega receptorja
EP06754324A EP1899333B1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
CY20091100501T CY1110464T1 (el) 2005-06-27 2009-05-11 Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05013774 2005-06-27
PCT/EP2006/005649 WO2007000241A1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
EP06754324A EP1899333B1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1

Publications (2)

Publication Number Publication Date
EP1899333A1 EP1899333A1 (en) 2008-03-19
EP1899333B1 true EP1899333B1 (en) 2009-02-18

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06754324A Active EP1899333B1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1

Country Status (30)

Country Link
US (1) US7910602B2 (enrdf_load_stackoverflow)
EP (1) EP1899333B1 (enrdf_load_stackoverflow)
JP (1) JP5010594B2 (enrdf_load_stackoverflow)
KR (1) KR20080020638A (enrdf_load_stackoverflow)
CN (1) CN101208340B (enrdf_load_stackoverflow)
AR (1) AR054514A1 (enrdf_load_stackoverflow)
AT (1) ATE423118T1 (enrdf_load_stackoverflow)
AU (1) AU2006264044A1 (enrdf_load_stackoverflow)
BR (1) BRPI0612320A2 (enrdf_load_stackoverflow)
CA (1) CA2611296A1 (enrdf_load_stackoverflow)
CY (1) CY1110464T1 (enrdf_load_stackoverflow)
DE (1) DE602006005242D1 (enrdf_load_stackoverflow)
DK (1) DK1899333T3 (enrdf_load_stackoverflow)
ES (1) ES2322197T3 (enrdf_load_stackoverflow)
HR (1) HRP20090244T2 (enrdf_load_stackoverflow)
IL (1) IL188381A0 (enrdf_load_stackoverflow)
MA (1) MA29498B1 (enrdf_load_stackoverflow)
MX (1) MX2007015829A (enrdf_load_stackoverflow)
MY (1) MY139016A (enrdf_load_stackoverflow)
NO (1) NO20080392L (enrdf_load_stackoverflow)
NZ (1) NZ564757A (enrdf_load_stackoverflow)
PL (1) PL1899333T3 (enrdf_load_stackoverflow)
PT (1) PT1899333E (enrdf_load_stackoverflow)
RS (1) RS50821B (enrdf_load_stackoverflow)
RU (1) RU2415855C2 (enrdf_load_stackoverflow)
SI (1) SI1899333T1 (enrdf_load_stackoverflow)
TW (1) TW200800982A (enrdf_load_stackoverflow)
UY (1) UY29632A1 (enrdf_load_stackoverflow)
WO (1) WO2007000241A1 (enrdf_load_stackoverflow)
ZA (1) ZA200709853B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009107391A1 (ja) * 2008-02-27 2009-09-03 武田薬品工業株式会社 ６員芳香環含有化合物
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
EP3870583A1 (en) * 2018-10-24 2021-09-01 Bristol-Myers Squibb Company Substituted indole and indazole compounds
CN112912382B (zh) 2018-10-24 2024-07-02 百时美施贵宝公司 经取代的吲哚二聚体化合物
US12187723B2 (en) 2019-05-09 2025-01-07 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
US12384760B2 (en) 2019-10-04 2025-08-12 Bristol-Myers Squibb Company Substituted carbazole compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ287613B6 (en) * 1994-06-16 2001-01-17 Pfizer Pyrazolo- and pyrrolopyridines and pharmaceutical preparations based thereon
ES2281941T3 (es) * 1997-12-13 2007-10-01 Bristol-Myers Squibb Company Uso de pirazolo(3,4-b)piridina como inhibidores de quinasa dependiente de ciclina.
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
BR0313262A (pt) * 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
CA2515197C (en) * 2003-02-27 2011-10-18 J. Uriach Y Compania S.A. Pyrazolopyridine derivates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Also Published As

Publication number Publication date
NZ564757A (en) 2009-12-24
ES2322197T3 (es) 2009-06-17
MX2007015829A (es) 2008-02-22
BRPI0612320A2 (pt) 2010-11-09
MY139016A (en) 2009-08-28
KR20080020638A (ko) 2008-03-05
RS50821B (sr) 2010-08-31
ATE423118T1 (de) 2009-03-15
US7910602B2 (en) 2011-03-22
HRP20090244T2 (hr) 2009-07-31
TW200800982A (en) 2008-01-01
PL1899333T3 (pl) 2009-07-31
AR054514A1 (es) 2007-06-27
NO20080392L (no) 2008-02-28
CN101208340A (zh) 2008-06-25
RU2415855C2 (ru) 2011-04-10
DK1899333T3 (da) 2009-06-15
DE602006005242D1 (de) 2009-04-02
SI1899333T1 (sl) 2009-08-31
MA29498B1 (fr) 2008-05-02
PT1899333E (pt) 2009-04-23
HRP20090244T1 (en) 2009-06-30
IL188381A0 (en) 2008-04-13
UY29632A1 (es) 2007-01-31
CN101208340B (zh) 2010-12-22
JP5010594B2 (ja) 2012-08-29
CA2611296A1 (en) 2007-01-04
CY1110464T1 (el) 2015-04-29
WO2007000241A1 (en) 2007-01-04
RU2008102970A (ru) 2009-08-10
EP1899333A1 (en) 2008-03-19
AU2006264044A1 (en) 2007-01-04
ZA200709853B (en) 2008-12-31
US20080227777A1 (en) 2008-09-18
JP2008543957A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
EP1899333B1 (en) Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
BR112019015707A2 (pt) Composto, composição farmacêutica. uso de um composto, combinação de um composto e dispositivo
US20110172244A1 (en) Compounds and compositions as modulators of gpr119 activity
PT2334672E (pt) Compostos novos i
EP3774780B1 (en) Compounds and their use as pde4 activators
CN103443076B (zh) 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
JP2013512952A (ja) インドールコアを含有する複素環化合物
TW200843743A (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin S
HUP0003413A2 (hu) Új kondenzált piridinszármazékok, eljárás előállításukra és az azokat tartalmazó gyógyászati készítmények
EP3679039B1 (en) Tyrosine analogues derivatives as rho- kinase inhibitors
WO2010026113A1 (en) Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
EP1430898A1 (en) Receptor antagonist
AU2003285160B2 (en) Fused heterocyclic compounds
JP4733648B2 (ja) マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体
WO2005048916A2 (en) Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
HK1122550A (en) Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1
EP0906308A1 (en) Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists
AU2004275937A1 (en) Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases
KR101315788B1 (ko) 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
JP2024511886A (ja) 新規の複素環式化合物およびその使用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20080128

Extension state: BA

Payment date: 20080128

Extension state: AL

Payment date: 20080128

Extension state: RS

Payment date: 20080128

Extension state: MK

Payment date: 20080128

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SMRCINA, MARTIN

Inventor name: WEI, LINLI

Inventor name: STEINHAGEN, HENNING

Inventor name: HUBER, JOCHEN

Inventor name: PIRARD, BERNARD

Inventor name: BJERGARDE, KIRSTEN

Inventor name: PATEK, MARCEL

Inventor name: RITTER, KURT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006005242

Country of ref document: DE

Date of ref document: 20090402

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090415

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20090244

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090401194

Country of ref document: GR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2322197

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20090244

Country of ref document: HR

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

Ref country code: HR

Ref legal event code: T2IS

Ref document number: P20090244

Country of ref document: HR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090618

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20090615

Year of fee payment: 4

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005686

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20090244

Country of ref document: HR

Payment date: 20100612

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20100515

Year of fee payment: 5

Ref country code: DK

Payment date: 20100610

Year of fee payment: 5

Ref country code: FI

Payment date: 20100610

Year of fee payment: 5

Ref country code: HU

Payment date: 20100527

Year of fee payment: 5

Ref country code: IE

Payment date: 20100614

Year of fee payment: 5

Ref country code: LU

Payment date: 20100614

Year of fee payment: 5

Ref country code: PT

Payment date: 20100521

Year of fee payment: 5

Ref country code: RO

Payment date: 20100511

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20100510

Year of fee payment: 5

Ref country code: EE

Payment date: 20100504

Year of fee payment: 5

Ref country code: IT

Payment date: 20100615

Year of fee payment: 5

Ref country code: LT

Payment date: 20100505

Year of fee payment: 5

Ref country code: LV

Payment date: 20100422

Year of fee payment: 5

Ref country code: PL

Payment date: 20100506

Year of fee payment: 5

Ref country code: SI

Payment date: 20100430

Year of fee payment: 5

Ref country code: SK

Payment date: 20100510

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100615

Year of fee payment: 5

Ref country code: CH

Payment date: 20100614

Year of fee payment: 5

Ref country code: ES

Payment date: 20100713

Year of fee payment: 5

Ref country code: NL

Payment date: 20100603

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20100609

Year of fee payment: 5

Ref country code: TR

Payment date: 20100521

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100514

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20100517

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20090244

Country of ref document: HR

Effective date: 20110614

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111213

BERE Be: lapsed

Owner name: SANOFI-AVENTIS

Effective date: 20110630

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120101

LTLA Lt: lapse of european patent or patent extension

Effective date: 20110613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111213

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E003134

Country of ref document: EE

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20120118

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 5834

Country of ref document: SK

Effective date: 20110613

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20090401194

Country of ref document: GR

Effective date: 20120105

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 423118

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110613

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110614

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120101

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20121116

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110614

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006005242

Country of ref document: DE

Owner name: SANOFI, FR

Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR

Effective date: 20130205

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006005242

Country of ref document: DE

Owner name: SANOFI-AVENTIS, FR

Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR

Effective date: 20130205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110613

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190528

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190510

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190612

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006005242

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210101